Search

Your search keyword '"Rotzinger, Susan"' showing total 416 results

Search Constraints

Start Over You searched for: Author "Rotzinger, Susan" Remove constraint Author: "Rotzinger, Susan"
416 results on '"Rotzinger, Susan"'

Search Results

1. Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study

2. Endocannabinoid concentrations in major depression: effects of childhood maltreatment and relation to hippocampal volume

3. Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo

4. Publisher Correction: Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo

5. AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale

6. Depression-Anxiety Coupling Strength as a predictor of relapse in major depressive disorder: A CAN-BIND wellness monitoring study report

7. Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder

9. A standardized workflow for long-term longitudinal actigraphy data processing using one year of continuous actigraphy from the CAN-BIND Wellness Monitoring Study

11. An empirical analysis of structural neuroimaging profiles in a staging model of depression

12. Relation of hippocampal volume and SGK1 gene expression to treatment remission in major depression is moderated by childhood maltreatment: A CAN-BIND-1 report

16. Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study

17. Alterations in the neural correlates of affective inhibitory control following cognitive behavioral therapy for depression: A Canadian biomarker integration network for depression (CAN-BIND) study

20. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study

24. Atypical brain aging and its association with working memory performance in major depressive disorder

25. Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report

27. White matter microstructure in youth at risk for serious mental illness: A comparative analysis

30. Functional neuroimaging biomarkers of anhedonia response to escitalopram plus adjunct aripiprazole treatment for major depressive disorder

33. Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report

34. Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report

35. Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report

37. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response

38. Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study

39. Anxious arousal predicts within-person changes in hippocampal volume in adults with a history of childhood maltreatment: A CAN-BIND4 report.

40. Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication

42. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study

43. The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols

44. Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report

45. 286. Genetic Polymorphism of Brain-Derived Neurotrophic Factor is Related to Antidepressant Efficacy and Treatment-Induced Hippocampal Plasticity in Patients With Major Depressive Disorder: CAN-BIND-1 Study

46. Influence of CYP2C19, CYP2D6, and ABCB1Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study

47. GPR56/ADGRG1 is associated with response to antidepressant treatment

48. The Differential Relation of Emotional, Physical, and Sexual Abuse Histories to Antidepressant Treatment Remission and Persistence of Anhedonia in Major Depression: A CAN-BIND-1 Report

49. AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale.

50. AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder:COORDINATE-MDD consortium design and rationale

Catalog

Books, media, physical & digital resources